Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-010223.pdf
0001179110-17-010223.rtf
0001179110-17-010223.xls
4/A

Amendment to a previously filed 4

 View HTML
0001179110-17-009848.pdf
0001179110-17-009848.rtf
0001179110-17-009848.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009850.pdf
0001179110-17-009850.rtf
0001179110-17-009850.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009851.pdf
0001179110-17-009851.rtf
0001179110-17-009851.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009853.pdf
0001179110-17-009853.rtf
0001179110-17-009853.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009852.pdf
0001179110-17-009852.rtf
0001179110-17-009852.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009516.pdf
0001179110-17-009516.rtf
0001179110-17-009516.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009519.pdf
0001179110-17-009519.rtf
0001179110-17-009519.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009518.pdf
0001179110-17-009518.rtf
0001179110-17-009518.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-17-009517.pdf
0001179110-17-009517.rtf
0001179110-17-009517.xls